Ericsson Supports Global Health Innovation Network in Singapore
Ericsson Supports Global Health Innovation Network in Singapore
The partnership was formalised through the signing of a Memorandum of Understanding (MoU) at the Singapore-Sweden Royal Business Forum, witnessed by State Secretary for Healthcare, Ms Miriam Söderström and Singapore's Permanent Secretary for Policy and Development, Ms Lai Wei Lin. The event was attended by Singapore's Minister for Health, Mr Ong Ye Kung.
该合作关系通过在新加坡-瑞典皇家商业论坛上签署谅解备忘录（MoU）形式化，见证人包括卫生国务秘书米莉亚姆·索德斯特伦和新加坡政策与发展常秘书赖维琳。此次活动由新加坡卫生部长王乙康出席。
GHIN will identify, implement, and scale health innovations in screening, diagnosis, and monitoring. The purpose of the GHIN is to facilitate the actual implementation of innovative technology, which is the major challenge globally in driving healthcare innovation forward.
GHIN将识别、实施和扩展筛查、诊断和监测领域的健康创新。GHIN的目的是促进创新技术的实际实施，这是全球推动医疗创新向前发展的主要挑战。
This collaboration marks the first concrete initiative under the government-to-government MoU on healthcare innovation collaboration, signed by Singapore and Sweden during the same event.
此次合作标志着在新加坡与瑞典于同一活动上签署的政府间医疗创新合作谅解备忘录下的首个具体举措。
Scaling innovations and sharing expertise
扩展创新与分享专业知识
The GHIN brings together various players in the healthcare, pharmaceutical and communication industries. NUHS and Sahlgrenska University Hospital will take on a shared role of providing clinical experience and knowledge, hospital resources for prototype testing and research, sharing research materials and publications as well as providing mentoring support. By leveraging their collective expertise, all the partners will work towards facilitating the development of novel technologies in healthcare, successful implementation and scaling up of these healthcare services.
GHIN汇聚了医疗、药品和通讯行业的各方参与者。NUHS和萨尔格伦斯卡大学医院将共同承担提供临床经验和知识、医院资源用于原型测试和研究、分享研究材料和出版物以及提供指导支持的角色。通过利用他们的集体专业知识，所有合作伙伴将共同努力促进医疗领域新技术的发展，以及这些医疗服务的成功实施和扩展。
"Implementing the newest technologies and leveraging opportunities from research and innovation worldwide strengthens global healthcare," states Dr Boubou Hallberg, CEO, Sahlgrenska University Hospital. "This collaboration also helps new treatments reach patients from all over the world faster."
“实施最新技术并利用全球研究和创新的机会，将加强全球医疗，”萨尔格伦斯卡大学医院首席执行官鲍布·霍尔贝格博士表示。“此合作还帮助新的治疗方法更快地到达来自全球各地的患者。”
"As an academic health system, we will bring together expertise in clinical care, research, and education to support this collaboration," states Adjunct Professor Jason Phua, Deputy Chief Executive (Clinical Transformation), NUHS.
“作为一个学术健康系统，我们将汇集临床护理、研究和教育方面的专业知识来支持这一合作，”NUHS临床转型副首席执行官助理教授贾森·普阿表示。
"When we combine our strengths with the unique capabilities of our partners, we can contribute meaningfully to the advancement of patient care and the improvement of global health."
“当我们将自身的优势与合作伙伴独特的能力结合在一起时，我们可以为提升患者护理和改善全球健康作出有意义的贡献。”
Ms Kim Suyeon, Country President, AstraZeneca Singapore says, "We are really excited to come onboard this meaningful collaboration, leveraging AstraZeneca's global healthcare innovation platform, A.Catalyst Network. As part of a broader network of ecosystem stakeholders, our role as a founding industry partner is to support the scouting of innovative solutions towards solving identified problem statements across the healthcare systems, potentially helping to scale effectively implemented solutions to other markets via our network."
阿斯利康新加坡的国家总裁金瑞妍女士表示："我们非常期待参与这项有意义的合作，利用阿斯利康的全球医疗创新平台A.Catalyst Network。作为生态系统利益相关者更广泛网络的一部分，我们作为创始行业合作伙伴的角色是支持寻找创新解决方案，以解决医疗系统中识别出的问题，同时可能有助于将有效实施的解决方案推广到我们网络中的其他市场。"
"High performance connectivity based on 5G will transform healthcare. By joining the GHIN as a founding partner, we will fuel innovation in healthcare services based on our ability to blend technological innovation with medical knowledge. With 5G, we can extend the reach of the healthcare system to many people for whom healthcare access and treatment is a challenge." says Mr Daniel Ode, Head of Ericsson Singapore, Philippines and Brunei.
"基于5G的高性能连接将会改变医疗服务。作为GHIN的创始合作伙伴，我们将促进医疗服务的创新，因为我们能够将科技创新与医疗知识相结合。有了5G，我们可以将医疗系统的覆盖面扩展到许多面临医疗接入和治疗挑战的人。" 新加坡、菲律宾和文莱爱立信负责人丹尼尔·奥德先生说道。
Business Sweden will serve as the project management office (PMO) for GHIN, facilitating collaboration and strengthening connections between Swedish, Singaporean, and international stakeholders.
瑞典商业局将作为GHIN的项目管理办公室（PMO），促进瑞典、新加坡和国际利益相关者之间的合作并加强联系。
"I am proud that Business Sweden can support GHIN and hope that we can enable a strong and productive collaboration. We will focus on expanding its reach by bringing in new partners and aim for faster adoption and larger scaling of healthcare innovations worldwide."
"我很自豪瑞典商业局能够支持GHIN，并希望我们能够推动强大而富有成效的合作。我们将专注于通过引入新合作伙伴来扩大其覆盖面，并致力于更快的采纳和更大规模的全球医疗创新。"
GHIN has been created as an open innovation ecosystem, welcoming collaborations with Swedish, Singaporean, and international stakeholders. While the establishment of the GHIN is still in the early stages, the founding members hope that more partners will come onboard in the years ahead, to amplify their collective efforts in creating more effective healthcare solutions globally.
GHIN作为一个开放的创新生态系统而建立，欢迎与瑞典、新加坡和国际利益相关者的合作。尽管GHIN的成立仍处于早期阶段，创始成员希望在未来的几年内能够有更多合作伙伴加入，以增强他们在创造更有效的全球医疗解决方案方面的集体努力。
NOTES TO EDITORS:
编辑注：
FOLLOW US:
关注我们：
Subscribe to Ericsson press releases here
Subscribe to Ericsson blog posts here
在此订阅爱立信新闻稿
在此订阅爱立信博客文章
MORE INFORMATION AT:
Ericsson Newsroom
media.relations@ericsson.com (+46 10 719 69 92)
investor.relations@ericsson.com (+46 10 719 00 00)
了解更多信息，请访问：
爱立信新闻室
media.relations@ericsson.com (+46 10 719 69 92)
investor.relations@ericsson.com (+46 10 719 00 00)
ABOUT ERICSSON:
关于爱立信：
Ericsson's high-performing networks provide connectivity for billions of people every day. For nearly 150 years, we've been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality.
爱立信的高效网络为每天的数十亿人提供连接。近150年来，我们一直致力于创建通信技术。我们为服务提供商和企业提供移动通信和连接解决方案。与客户和合作伙伴一起，我们将明日数字世界变为现实。
ABOUT THE NATIONAL UNIVERSITY HEALTH SYSTEM (NUHS)
关于国立大学健康系统（NUHS）
The National University Health System (NUHS) aims to transform how illness is prevented and managed by discovering causes of disease, development of more effective treatments through collaborative multidisciplinary research and clinical trials, and creation of better technologies and care delivery systems in partnership with others who share the same values and vision.
国家大学健康系统（NUHS）的目标是通过发现疾病的原因、通过跨学科的协作研究和临床试验开发更有效的治疗方法，以及与共享相同价值观和愿景的其他合作伙伴共同创建更好的技术和护理交付系统，来改进疾病的预防和管理。
Institutions in the NUHS Group include the National University Hospital, Ng Teng Fong General Hospital, Jurong Community Hospital and Alexandra Hospital; three National Specialty Centres - National University Cancer Institute, Singapore (NCIS), National University Heart Centre, Singapore (NUHCS) and National University Centre for Oral Health, Singapore (NUCOHS); the National University Polyclinics (NUP); Jurong Medical Centre; and three NUS health sciences schools – NUS Yong Loo Lin School of Medicine (including the Alice Lee Centre for Nursing Studies), NUS Faculty of Dentistry and NUS Saw Swee Hock School of Public Health.
NUHS集团的机构包括国家大学医院、黄廷芳综合医院、裕廊社区医院和亚历山大医院；三个国家专业中心——新加坡国家大学癌症研究所（NCIS）、新加坡国家大学心脏中心（NUHCS）和新加坡国家大学口腔健康中心（NUCOHS）；国家大学门诊（NUP）；裕廊医疗中心；以及三所NUS健康科学学院——NUS杨璐琳医学院（包括爱丽丝李护理研究中心）、NUS牙科学院和NUS苏瑞霍公共卫生学院。
With member institutions under a common governance structure, NUHS creates synergies for the advancement of health by integrating patient care, health science education and biomedical research.
在共同行政架构下，NUHS通过整合病人护理、健康科学教育和生物医药研究，为健康的推进创造协同效应。
As a Regional Health System, NUHS works closely with health and social care partners across Singapore to develop and implement programmes that contribute to a healthy and engaged population in the Western part of Singapore.
作为一个区域型健康系统，NUHS与新加坡各地的健康和社会护理合作伙伴密切合作，开发和实施有助于新加坡西部地区健康和积极参与人口的项目。
For more information, please visit .
更多资讯，请访问。
ABOUT ASTRAZENECA
关于阿斯利康
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
阿斯利康（LSE/STO/纳斯达克：AZN）是一家全球性的、以科学为主导的药品公司，专注于肿瘤学、罕见疾病和生物医药等领域的处方药的发现、开发和商业化，包括心血管、肾脏与代谢，以及呼吸与免疫学。阿斯利康总部位于英国剑桥，其创新药物在125多个国家销售，全球数百万患者使用。请访问astrazeneca.com，并在社交媒体上关注公司@AstraZeneca。
